Par ticks up, having gained 14 percent on Ultram patent ruling and generic Catapres approval (Minneapolis-St. Paul Star Tribune)

Par ticks up, having gained 14 percent on Ultram patent ruling and generic Catapres approval (Minneapolis-St. Paul Star Tribune)
NEW YORK – Shares of Par Pharmaceutical Cos. continued to rise Friday, capping a week where the company won a patent challenge that could allow it to start selling a generic version of a pain drug, and won FDA approval of a generic blood pressure patch.